Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.
Emmes Announces its Contribution to Second Remdesivir Clinical Trial for COVID-19
Emmes today announced that it has conducted the data and statistical analysis for the second iteration of the Adaptive COVID-19 Treatment Trial (ACTT-2). The ACTT-2 trial assessed the efficacy and safety of a 4-mg dose of baricitinib with remdesivir, versus remdesivir alone, in hospitalized COVID-19 patients. Baricitinib, produced by Eli Lilly and Company, has been used to treat adults with moderate to severe rheumatoid arthritis. Baricitinib, in combination with remdesivir for COVID-19 patients, received Emergency Use Authorization on November 19.
Emmes Employees Co-Author COVID-19 Vaccine Report for the New England Journal of Medicine
Emmes today announced that it provided the data and statistical analysis support for a Phase 1 clinical trial of an investigational COVID-19 vaccine, mRNA-1273, that enrolled adult volunteers. The results of this clinical trial were published in the New England Journal of Medicine (NEJM) on September 29. Three Emmes employees were among the co-authors of the recent report, “Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.” The employees are Jim Albert, lead project manager; Dr. Mat Makowski, senior biostatistician; and Kaitlyn Cross, senior biostatistician.
Life sciences firm’s new CEO talks expansion plans during Covid-19 pandemic
Dr. Christine Dingivan, Emmes president and CEO, was recently interviewed by Washington Business Journal reporter Sara Gilgore. In the interview Christine talks about her vision for the company, growth opportunities, and the company's strengths. She also discusses how the current COVID-19 pandemic has impacted the drug development industry, both short term and long term.
Emmes Selected as Corporate Achievement Award Winner by the Montgomery County Chamber of Commerce
Emmes today announced that the Montgomery County Chamber of Commerce has selected Emmes as the recipient of its 2020 Corporate Achievement Award. Dr. Anne Lindblad, who recently retired as the company’s president and chief executive officer, accepted the award at a virtual event hosted by the chamber on October 29. According to Lowell Yoder, chairman of the Montgomery County Chamber of Commerce and M&T Bank’s group vice president for the Greater Washington Market, “Over the years, Emmes has set high standards for financial performance, sound management, and sustained growth – while contributing significantly to our community along the way.”
The Washington Post Announces Top Workplace Rankings
Emmes today announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2020 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post partnered with employee research and consulting firm Energage, and the process is based on a scientific survey of employees who rate their workplace culture. The Post’s annual survey honored 200 organizations as Top Workplaces. Emmes was selected in the large company category, which included organizations with between 500 and 999 employees. More than 3,600 area companies were invited to have their employees take the survey.
Dr. Christine Dingivan Joins Emmes as President and CEO
Emmes today announced that Dr. Christine Dingivan has joined the company as its new president and chief executive officer. She is succeeding Dr. Anne Lindblad, who is retiring after 38 years at the company. Dr. Dingivan will be Emmes’ fourth chief executive since the company was founded in 1977.
Emmes Announces its Role in Phase 1 COVID-19 Vaccine Trial
Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273. Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, “An mRNA Vaccine against SARS-CoV-2,” published in the New England Journal of Medicine on July 14.
Emmes Promotes Three VPs to Officer Positions
Emmes today announced that three corporate vice presidents have been promoted. Dr. Traci Clemons has been named chief research officer, Marian Ewell is now chief scientific innovation officer, and Jennifer Hester is the company’s chief human resources officer. These are all newly created positions for the company. According to Dr. Anne Lindblad, president and chief executive officer, “Elevating these roles – research, scientific innovation, and human resources – is a tremendous step forward in our company’s evolution. It’s an endorsement for how far we’ve come as a major player supporting clinical trials and research for a wide range of human health issues. It reflects our growth and diversification across both government and commercial sectors. And finally, it’s a testament to the value of these three outstanding professionals, and the role they’ve played and will continue to play in our success.”
NEOX recognized in the Basal Insulin study publication
Neox is honored to be recognized in a recent publication in Scientific Research. Please join us in congratulating all our colleagues who contributed, especially to Jana Maskova.
Emmes Chosen as a Top Area Workplace
Emmes today announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2020 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post partnered with employee research and consulting firm Energage, LLC, to conduct the survey, and the highest ranked workplaces were chosen based on employee responses about their own company. There were 3,500 area companies invited to participate, and 406 were surveyed. This is the seventh year the survey has been conducted.
Emmes Announces Its Work on a Phase 3 Clinical Trial for Breakthrough Therapy Designation Product
Emmes today announced that it provided the Phase 3 clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant. Emmes’ work for Gamida Cell Ltd. , an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, involved full scope clinical trial support for this study that was conducted at more than 50 centers in the United States, Latin America, Europe and Asia. Emmes also supported the early development Phase 1 and 2 trials that began in 2010.
Emmes Announces its Contribution to NIH ACTT Clinical Trial for Remdesivir
Emmes today announced that its data and statistical analysis work for the Adaptive COVID-19 Treatment Trial (ACTT) played an important role in the accelerated timetable to evaluate remdesivir’s effectiveness in treating hospitalized COVID-19 patients.